Keefe, Bruyette & Woods reaffirmed their mkt perform rating on shares of Safeguard Scientifics (NYSE:SFE) in a research report report published on Wednesday morning. The brokerage currently has a $13.25 target price on the asset manager’s stock.
Several other research firms also recently weighed in on SFE. Zacks Investment Research upgraded Safeguard Scientifics from a hold rating to a buy rating and set a $16.00 price target on the stock in a research note on Thursday, November 2nd. ValuEngine downgraded Safeguard Scientifics from a hold rating to a sell rating in a research note on Tuesday, November 14th.
Shares of Safeguard Scientifics (NYSE:SFE) traded down $0.10 during trading hours on Wednesday, hitting $11.90. The stock had a trading volume of 36,800 shares, compared to its average volume of 64,688. Safeguard Scientifics has a 12-month low of $10.65 and a 12-month high of $14.40. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 1.03.
Safeguard Scientifics (NYSE:SFE) last posted its quarterly earnings results on Thursday, October 26th. The asset manager reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.20. During the same period in the previous year, the company posted ($1.18) earnings per share. equities research analysts forecast that Safeguard Scientifics will post -4.47 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of SFE. Vanguard Group Inc. boosted its stake in Safeguard Scientifics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 828,897 shares of the asset manager’s stock valued at $10,528,000 after purchasing an additional 15,086 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Safeguard Scientifics by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 146,721 shares of the asset manager’s stock worth $1,863,000 after buying an additional 6,742 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Safeguard Scientifics by 6.3% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,757 shares of the asset manager’s stock worth $1,102,000 after buying an additional 5,130 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Safeguard Scientifics by 8.2% in the 1st quarter. Bank of America Corp DE now owns 25,289 shares of the asset manager’s stock worth $321,000 after buying an additional 1,907 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Safeguard Scientifics by 12.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 15,336 shares of the asset manager’s stock worth $195,000 after buying an additional 1,754 shares during the last quarter. Institutional investors and hedge funds own 76.29% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.thestockobserver.com/2017/12/07/safeguard-scientifics-sfe-mkt-perform-rating-reaffirmed-at-keefe-bruyette-woods.html.
Safeguard Scientifics Company Profile
Safeguard Scientifics, Inc is engaged in providing capital to technology companies within the fields of healthcare, financial services and digital media. The Company holds interest in companies, which it refers to as partner companies. As of December 31, 2016, the Company held interests in 29 non-consolidated partner companies.
Receive News & Ratings for Safeguard Scientifics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Safeguard Scientifics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.